348 related articles for article (PubMed ID: 38333084)
1. Design and engineering of bispecific antibodies: insights and practical considerations.
Madsen AV; Pedersen LE; Kristensen P; Goletz S
Front Bioeng Biotechnol; 2024; 12():1352014. PubMed ID: 38333084
[TBL] [Abstract][Full Text] [Related]
2. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats.
Madsen AV; Kristensen P; Buell AK; Goletz S
MAbs; 2023; 15(1):2189432. PubMed ID: 36939220
[TBL] [Abstract][Full Text] [Related]
3. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ
Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352
[TBL] [Abstract][Full Text] [Related]
4. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
5. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
7. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
[TBL] [Abstract][Full Text] [Related]
8. Building blocks for bispecific and trispecific antibodies.
Wu X; Demarest SJ
Methods; 2019 Feb; 154():3-9. PubMed ID: 30172007
[TBL] [Abstract][Full Text] [Related]
9. A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities.
Li Y
Protein Expr Purif; 2019 Mar; 155():112-119. PubMed ID: 30513344
[TBL] [Abstract][Full Text] [Related]
10. Bioassay Development for Bispecific Antibodies-Challenges and Opportunities.
Register AC; Tarighat SS; Lee HY
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069573
[TBL] [Abstract][Full Text] [Related]
11. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.
Ha JH; Kim JE; Kim YS
Front Immunol; 2016; 7():394. PubMed ID: 27766096
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy.
Chen S; Li L; Zhang F; Wang Y; Hu Y; Zhao L
J Immunol Res; 2019; 2019():4516041. PubMed ID: 30886871
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
15. Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells.
Watanabe Y; Tanabe A; Hamakubo T; Nagatoishi S; Tsumoto K
J Biochem; 2021 Oct; 170(2):307-315. PubMed ID: 33844018
[TBL] [Abstract][Full Text] [Related]
16. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
17. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.
Mabry R; Snavely M
IDrugs; 2010 Aug; 13(8):543-9. PubMed ID: 20721825
[TBL] [Abstract][Full Text] [Related]
19. Acid pH promotes bispecific antibody formation by the redox procedure.
Gupta J; Hoque M; Ahmad MF; Khan RH; Saleemuddin M
Int J Biol Macromol; 2019 Mar; 125():469-477. PubMed ID: 30528998
[TBL] [Abstract][Full Text] [Related]
20. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
